• Researcher Profile

    Holcombe E. Grier, MD

     
    Holcombe E. Grier, MD
     
    Institute Physician

    Professor of Pediatrics, Harvard Medical School

    Center/Program

    Pediatric Solid Tumors

    Office phone: 617-632-3971
    Fax: 617-632-5710
    Email: holcombe_grier@dfci.harvard.edu

    Preferred contact method: office phone

    View Physician Profile
     
     

    Research Department

    Pediatric Oncology

    Interests

    Ewing sarcoma, Osteosarcoma, Rhabdomyosarcoma, Non-rhabdo soft tissue sarcoma

    Area of Research

    Pediatric Sarcomas

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana G350
    Boston, MA 02215

    Biography

    Dr. Grier received his MD from the University of Pennsylvania in 1976, and then trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina. He joined Dana-Farber Cancer Institute in 1984. He is a past president of the American Society of Pediatric Hematology/Oncology and is a member of the steering committee for Bone Tumors in the Children's Oncology Group.

    Recent Awards

    • Harvard Medical School Community Service Award, 2009
    • Harvard Medical School Faculty Prize for Excellence in Teaching [Years III and IV], 2008
    • Ronald L Chard, Jr. Memorial Lecture, Childrens Hospital and Memorial Medical Center, Seattle, WA., 2008
    • Stephen Sallan Leadership Award, Dana Farber Cancer Institute, Boston, MA, 2007
    • Charles A. Janeway Award for Excellence in Clinical Teaching, Children's Hospital House Staff, Boston, 1992

    Research

    Pediatric Sarcomas

    At the Children's Oncology Group, we work on the design and implementation of studies regarding Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries. Dr. Grier is an active member of the Bone Tumor Disease Committee and the Soft Tissue Sarcoma Committee of this group.

    As part of the Pediatric Solid Tumor group at DFCI and Children's Hospital, we help organize laboratory and clinical cross talk.

    We are also involved in cancer survivor studies that focus on the late effects of chemotherapy. These studies are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at DFCI. In addition, we participate in a study of the best application of palliative care through our work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.

    Select Publications

    • Marcus KJ, Shamberger R, Litman H, von Allmen D, Grupp SA, Nancarrow CM, Goldwein J, Grier HE, Diller L. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003;25:934-40.
    • Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
      Clin Cancer Res 2003;9:5442-53.
    • Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005:2004-11.
    • Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
    • Mack JW, Grier HE. The day one talk. J Clin Oncol 2004;22:563-6.
    • Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23:4031-8.
    • Granowetter L, Womer RB, Devidas M, Krailo MD, Wang C, Bernstein ML, Marina N, Leavey PJ, Gebhardt M, Healey JH, Shamberger RC, Goorin AM, Miser J, Meyer M, Arndt CAS, Sayler S, Marcus KJ, Perlman EJ, Dickman PS, Grier HE: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.J Clin Oncol 27:2536-2541, 2009.

    Trainees

    • Dubois, Steve, MD
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now